Comparison of safety and efficac y of short-term treatment between re-use and initial use in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors / 中华风湿病学杂志

ABSTRACT

Objective To investigate the possible differences in safety and efficacy between re-use and initial use in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi). Methods From October 2016 to October 2017, 82 patients with AS who were admitted to the Second Hospital of Lanzhou University were studied. Among them, 57 patients used TNFi for the first time and 25 patients reuse it after the interruption. After 3 months of standardized use of TNF-inhibitor, we compared the efficacy indicators [visual analogue scale/score (VAS), morning stiffness, bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis metroloty index (BASMI), ankylosing spondylitis disease activity score (ASDAS), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) 0 and safety events between the two groups. T test and covariance analysis were used. Results The efficacy indexes of the two groups after treatment were significantly improved, the difference was statistically significant (P<0.05) compared with the baseline [Before and after treatment in the first treatment group ESR (40±31) mm/1 h, (8±8) mm/1 h, CRP (28±35) mg/L, (5±9) mg/L, VAS (6.5±1.6), (2.0 ±1.7), Morning stiff time (0.6 ±0.4) h, (0.1 ±0.2) h, BASDAI (5.0 ±1.3) h, (1.6 ±1.2) h, BASFI (4.1 ±2.3), (1.3±1.3), BASMI (2.6±2.0), (0.8±1.0), ASDAS (3.5±0.8), (1.2±0.7); Before and after treatment in the re-use group ESR (39 ±33) mm/1 h, (9 ±10) mm/1 h, CRP (28 ±28) mg/L, (5 ±6) mg/L, VAS (6.6 ±1.9), (1.6 ±1.0), Morning stiff time(0.6±0.4) h, (0.1±0.1) h, BASDAI(5.1±0.8), (1.4±1.4), BASFI (5.1±2.2), (1.3±1.4), BASMI(3.4 ±1.8), (1.0 ±0.9), ASDAS (3.6 ±0.8), (1.2 ±0.4)]. But there was no statistical significant difference between the two groups in patients after treatment (P>0.05). Conclusion Patients with AS who re-uses TNFi after discontinuation could achieve the same safety and efficacy as they first use it.